Paul Dark remembers the moment his team realized they might have found a better way to protect sepsis patients — not by giving more treatment, but by knowing when to stop it. In intensive care units across the United Kingdom, doctors have long faced a painful dilemma: keep patients on powerful antibiotics to be safe, or risk stopping too soon and losing a life. Now, a major study involving 2,760 patients in 41 hospitals has shown that a simple daily blood test can help doctors make that call with greater confidence — and stop antibiotics nearly two days earlier than before.
Sepsis kills thousands every year. It happens when the body’s response to infection spirals out of control, damaging its own tissues and organs. Patients in intensive care often receive long courses of antibiotics because doctors fear the infection could return. But keeping patients on these drugs longer than needed carries serious risks — including antibiotic resistance, which the World Health Organization calls one of the biggest threats to global health.
The study, led by researchers at the University of Manchester and the Northern Care Alliance NHS Foundation Trust, tested a blood marker called procalcitonin (PCT). Every day, the patient’s blood was checked, and doctors received automated advice on whether antibiotics could be safely stopped. The results were clear: PCT-based guidance suggested stopping treatment nearly two days earlier than the more commonly used marker, C-reactive protein (CRP). Over the course of the trial, more than 17,000 blood samples were analyzed, offering the most detailed look yet at how these tools work in real hospitals.
Interestingly, doctors were more likely to follow CRP-based advice — likely because it aligns more closely with current practice. But the earlier signals from procalcitonin could lead to significantly less antibiotic use, which is crucial in the fight against drug-resistant infections. Some doctors hesitated to stop treatment due to existing hospital guidelines that recommend fixed durations, or because patients still had a fever or high inflammation levels. Still, the study shows that with the right support, change is possible.
Professor Paul Dark put it simply: 'Nobody wants to stop antibiotics too early and risk a patient's life, but continuing them unnecessarily also carries real dangers.' The goal isn’t to cut corners — it’s to give patients exactly the treatment they need, for exactly as long as they need it. With antimicrobial resistance on the rise, tools like this could help preserve life-saving drugs for future generations. As hospitals consider adopting this approach across the NHS, the message is clear: sometimes, the most powerful medicine is knowing when to stop.
